Contact us
Share

MX.3
FOR CAPITAL CHARGES: SA-CCR

ACHIEVE REGULATORY COMPLIANCE, REAL-TIME LIMITS AND CAPITAL MANAGEMENT

BCBS 279, the Basel Committee’s final text on the Standardised Approach for measuring Counterparty Credit Risk exposures (SA-CCR) raises real challenges for the industry. Tight implementation deadlines are coupled with heavier data management requirements and the necessity to interpret the regulatory rules to adequately map complex or exotic transactions to the appropriate regulatory delta and PFE criteria.

Murex's enterprise-wide SA-CCR solution addresses these challenges by leveraging a highly configurable and version-independent packaging.  The solution integrates natively within the MX.3 framework to deliver real-time risk and capital management.

SECURING REGULATORY COMPLIANCE WITH OPTIMAL TIME TO MARKET

MX.3 provides an out-of-the-box, configuration based solution for easy and timely deployment and supports trades held in MX.3 and in other trading systems. The pre-packaged EAD calculations include mapping facilities for complex and cross-asset products and the centralized configuration offers transparent access to supervisory factors and calculation rules.

REAL-TIME EXPOSURES AND CAPITAL ANALYSIS

MX.3 produces SA-CCR & RWA results in real-time and for pre-trade capital consumption analysis. Comparison of SA-CCR, CEM and IMM approaches is available online enabling identification of the optimal counterparty for the trade based on ‘Total cost of Trading’.
MX.3 for Risk Control supports pre-deal limits on SA-CCR, or SA-CCR-derived metrics, along with other internal risk measures, thus enabling real-time regulatory restrictions and alerts.

Transparency through all SA-CCR interim results (directional delta, adjusted notional, supervisory duration, maturity factor, PFE, Replacement Cost, NICA…) and through all netting and hedging sets aggregation levels is available.

 

If you wish to learn more about our SA-CCR solution, please download the flyer here.

Functional Coverage

Contact us

Please select
  • Information
    Request
  • Partnership
    Opportunity
  • Media/Analyst
    Inquiry

Information Request

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The information collected is processed for the sole use of Murex SAS in ad hoc communications and is therefore subject to dispensation no. 7 of the Commission National Informatique et Libertés (or 'CNIL', the French data protection authority). Pursuant to French Act No. 78-17 of 6 January 1978 as amended in 2004 (the French Data Protection Act), you have the right to access and rectify your personal information or data and the right to object to the processing of such data by contacting mkg@murex.com.

Partnership Opportunity

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The information collected is processed for the sole use of Murex SAS in ad hoc communications and is therefore subject to dispensation no. 7 of the Commission National Informatique et Libertés (or 'CNIL', the French data protection authority). Pursuant to French Act No. 78-17 of 6 January 1978 as amended in 2004 (the French Data Protection Act), you have the right to access and rectify your personal information or data and the right to object to the processing of such data by contacting mkg@murex.com.

Media/Analyst Inquiry

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The information collected is processed for the sole use of Murex SAS in ad hoc communications and is therefore subject to dispensation no. 7 of the Commission National Informatique et Libertés (or 'CNIL', the French data protection authority). Pursuant to French Act No. 78-17 of 6 January 1978 as amended in 2004 (the French Data Protection Act), you have the right to access and rectify your personal information or data and the right to object to the processing of such data by contacting mkg@murex.com.